Donna,
Here are the latest
HER2 Testing Guidelines < Click
The second paragraph states:
The National Comprehensive Cancer Network (NCCN) convened an expert task force after reports of HER2 testing problems encountered in clinical studies involving adjuvant breast cancer therapies.
4 The NCCN Task Force concluded that “
accurate assignment of the HER2 status of invasive breast cancer is essential to clinical decision making in the treatment of breast cancer in both adjuvant (early stage) and metastatic settings.”
Regards
Joe
Threaded Mode